Snowflake and SAP Unite to Eliminate Enterprise Data Silos in Significant AI Integration Effort
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Should l Buy AZN?
Source: Benzinga
Collaboration Announcement: Snowflake Inc. and SAP SE have partnered to integrate Snowflake's AI Data Cloud with SAP's Business Data Cloud, enhancing access to real-time data for AI applications and improving operational efficiency.
Integration Benefits: The collaboration allows for zero-copy data sharing, enabling businesses to analyze critical information without duplication, while also supporting large-scale analysis and maintaining governance.
Early Adoption: AstraZeneca is among the first to utilize this technology, leveraging it to accelerate medical research through real-time insights.
Future Developments: The SAP Snowflake integration is expected to be generally available in Q1 2026, with additional features and tools being introduced by both companies to enhance their AI capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AZN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 102.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 204.760
Low
95.00
Averages
102.75
High
108.00
Current: 204.760
Low
95.00
Averages
102.75
High
108.00
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CSPC Unveils Record Licensing Deal with AstraZeneca Amid Stock Decline
- Deal Details: CSPC's collaboration with AstraZeneca grants the latter exclusive global rights to CSPC's developing anti-obesity drugs, including SYH2082, yet the market's tepid response has led to a stock price decline following the announcement.
- Financial Performance Pressure: CSPC reported a 12.32% year-over-year revenue drop to 19.89 billion yuan and a 7.1% decline in net profit to 3.51 billion yuan in the first three quarters of 2025, highlighting the severe impact of China's centralized procurement policies on its core drug business.
- Executive Changes and Strategic Shift: The appointment of Cai Lei as CEO signals CSPC's commitment to accelerating its transition to innovative drugs, leveraging his experience from the U.S. R&D division to enhance global competitiveness.
- Market Reaction and Governance Risks: Despite the licensing deal's potential value of $18.5 billion, investor confidence has been undermined by corporate governance issues and insider trading scandals, resulting in a stock price drop post-announcement.
See More
AstraZeneca's ACT on Health Equity Receives $3.4 Million Support
- Funding Support: AstraZeneca has awarded $3.4 million to nonprofit organizations through its ACT on Health Equity initiative, totaling over $18 million to date, aimed at eliminating social and cultural barriers in healthcare, thereby enhancing community health outcomes.
- Project Coverage: In its fifth year, ACT will fund 47 nonprofit programs focusing on healthcare access, nutrition, and lung health, directly impacting vulnerable populations at higher risk for preventable diseases and advancing health equity.
- Community Solutions Challenge: The 2025 Community Solutions Challenge has awarded $1.11 million to 37 nonprofit organizations, providing each with $30,000 to address issues like food insecurity and lung health, thereby improving the quality of life for those affected by chronic conditions.
- Strategic Collaborations: The 2025 National Strategic Collaborations has allocated $2.3 million to 10 organizations, leveraging AstraZeneca's expertise in lung disease and cancer to eliminate barriers preventing underserved populations from receiving standard care, ultimately improving health outcomes.
See More
NIH Discontinues Low-Dose Rivaroxaban Trial Amid Safety Concerns
- Trial Discontinuation Reason: The NIH has halted the low-dose rivaroxaban arm of the CAPTIVA stroke prevention trial due to an independent safety review that identified increased safety events, indicating that the treatment is unlikely to provide benefits for the 1,683 enrolled participants.
- Safety Evaluation: This decision follows recommendations from the Data Safety and Monitoring Board, which oversees participant safety, highlighting NIH's commitment to participant welfare and a cautious approach towards new therapies.
- Trial Design Context: The CAPTIVA trial aims to assess whether rivaroxaban or ticagrelor is superior to clopidogrel in reducing the rates of ischemic stroke, intracerebral hemorrhage, or vascular death, involving over 100 sites and spanning four years.
- Market Reaction: Despite the trial's discontinuation, Johnson & Johnson's stock rose by 1.09% to $240.95 at the time of publication, reflecting market confidence in the company's other business segments, although this event may negatively impact the outlook for related products.
See More
AstraZeneca Executive Indicted in China
- Executive Indictment: Leon Wang, former president of AstraZeneca's China operations, has been indicted by Chinese prosecutors for unlawful collection of personal information, illegal trade, and medical insurance fraud, indicating significant legal risks for the company's operations in China.
- Stock Price Impact: Following reports of Wang's detention in October 2024, AstraZeneca's shares fell, reflecting market concerns regarding the company's operational stability and potential financial repercussions in the region.
- Revenue Dependency: China accounts for approximately 11% of AstraZeneca's revenue, contributing $58.7 billion in total revenue for 2025, and Wang's legal issues could adversely affect the company's profitability in this crucial market.
- Ongoing Legal Challenges: In its Q4 2025 earnings report, AstraZeneca disclosed that besides Wang, other executives are also facing similar charges, highlighting the urgent need for improved corporate governance and compliance measures within the company.
See More
AstraZeneca Awards $3.4 Million to 47 Nonprofits for Health Equity Initiatives
- Funding Milestone: AstraZeneca has awarded $3.4 million to 47 nonprofit organizations through its ACT initiative, bringing total contributions to over $18 million, demonstrating the company's ongoing commitment to advancing health equity.
- Community Solutions Challenge: As part of the 2025 Community Solutions Challenge, 37 nonprofits will receive $30,000 each, totaling $1.11 million, to tackle issues like food insecurity, nutritional education, and access to care for asthma, COPD, and lung cancer patients.
- National Strategic Collaborations: AstraZeneca will distribute $2.3 million to 10 organizations under the National Strategic Collaborations program, supporting initiatives related to lung disease, lung and breast cancer, and cardiology, aimed at addressing barriers for underserved populations.
- Positive Market Reaction: AstraZeneca's stock rose 3.29% in premarket trading to $199.77, reflecting investor recognition of the company's proactive actions in the health equity space.
See More
Paramount Enhances Warner Bros. Bid with Ticking Fee
- Bid Enhancement: Paramount has added a $0.25 per share 'ticking fee' to its hostile bid for Warner Bros. Discovery, maintaining its cash offer at $30 per share, which reflects its confidence in swift regulatory approval.
- Financial Commitment: Paramount will cover a $2.8 billion termination fee to Netflix if the merger with Warner Bros. is canceled, demonstrating its strong commitment to providing value to Warner Bros. shareholders.
- Nuclear IPO Filing: Holtec International has confidentially filed for an IPO that could value the company at over $10 billion, making it one of the largest in the nuclear sector, with annual revenues exceeding $500 million.
- AstraZeneca's Drug Strategy: AstraZeneca plans to introduce competitively priced weight-loss drugs to address market pressures in the U.S., with CEO Pascal Soriot emphasizing the enormous global demand and the potential for lower production costs to expand access.
See More
CSPC Unveils Record Licensing Deal with AstraZeneca Amid Stock Decline
- Deal Details: CSPC's collaboration with AstraZeneca grants the latter exclusive global rights to CSPC's developing anti-obesity drugs, including SYH2082, yet the market's tepid response has led to a stock price decline following the announcement.
- Financial Performance Pressure: CSPC reported a 12.32% year-over-year revenue drop to 19.89 billion yuan and a 7.1% decline in net profit to 3.51 billion yuan in the first three quarters of 2025, highlighting the severe impact of China's centralized procurement policies on its core drug business.
- Executive Changes and Strategic Shift: The appointment of Cai Lei as CEO signals CSPC's commitment to accelerating its transition to innovative drugs, leveraging his experience from the U.S. R&D division to enhance global competitiveness.
- Market Reaction and Governance Risks: Despite the licensing deal's potential value of $18.5 billion, investor confidence has been undermined by corporate governance issues and insider trading scandals, resulting in a stock price drop post-announcement.
See More
AstraZeneca's ACT on Health Equity Receives $3.4 Million Support
- Funding Support: AstraZeneca has awarded $3.4 million to nonprofit organizations through its ACT on Health Equity initiative, totaling over $18 million to date, aimed at eliminating social and cultural barriers in healthcare, thereby enhancing community health outcomes.
- Project Coverage: In its fifth year, ACT will fund 47 nonprofit programs focusing on healthcare access, nutrition, and lung health, directly impacting vulnerable populations at higher risk for preventable diseases and advancing health equity.
- Community Solutions Challenge: The 2025 Community Solutions Challenge has awarded $1.11 million to 37 nonprofit organizations, providing each with $30,000 to address issues like food insecurity and lung health, thereby improving the quality of life for those affected by chronic conditions.
- Strategic Collaborations: The 2025 National Strategic Collaborations has allocated $2.3 million to 10 organizations, leveraging AstraZeneca's expertise in lung disease and cancer to eliminate barriers preventing underserved populations from receiving standard care, ultimately improving health outcomes.
See More
NIH Discontinues Low-Dose Rivaroxaban Trial Amid Safety Concerns
- Trial Discontinuation Reason: The NIH has halted the low-dose rivaroxaban arm of the CAPTIVA stroke prevention trial due to an independent safety review that identified increased safety events, indicating that the treatment is unlikely to provide benefits for the 1,683 enrolled participants.
- Safety Evaluation: This decision follows recommendations from the Data Safety and Monitoring Board, which oversees participant safety, highlighting NIH's commitment to participant welfare and a cautious approach towards new therapies.
- Trial Design Context: The CAPTIVA trial aims to assess whether rivaroxaban or ticagrelor is superior to clopidogrel in reducing the rates of ischemic stroke, intracerebral hemorrhage, or vascular death, involving over 100 sites and spanning four years.
- Market Reaction: Despite the trial's discontinuation, Johnson & Johnson's stock rose by 1.09% to $240.95 at the time of publication, reflecting market confidence in the company's other business segments, although this event may negatively impact the outlook for related products.
See More
AstraZeneca Executive Indicted in China
- Executive Indictment: Leon Wang, former president of AstraZeneca's China operations, has been indicted by Chinese prosecutors for unlawful collection of personal information, illegal trade, and medical insurance fraud, indicating significant legal risks for the company's operations in China.
- Stock Price Impact: Following reports of Wang's detention in October 2024, AstraZeneca's shares fell, reflecting market concerns regarding the company's operational stability and potential financial repercussions in the region.
- Revenue Dependency: China accounts for approximately 11% of AstraZeneca's revenue, contributing $58.7 billion in total revenue for 2025, and Wang's legal issues could adversely affect the company's profitability in this crucial market.
- Ongoing Legal Challenges: In its Q4 2025 earnings report, AstraZeneca disclosed that besides Wang, other executives are also facing similar charges, highlighting the urgent need for improved corporate governance and compliance measures within the company.
See More
AstraZeneca Awards $3.4 Million to 47 Nonprofits for Health Equity Initiatives
- Funding Milestone: AstraZeneca has awarded $3.4 million to 47 nonprofit organizations through its ACT initiative, bringing total contributions to over $18 million, demonstrating the company's ongoing commitment to advancing health equity.
- Community Solutions Challenge: As part of the 2025 Community Solutions Challenge, 37 nonprofits will receive $30,000 each, totaling $1.11 million, to tackle issues like food insecurity, nutritional education, and access to care for asthma, COPD, and lung cancer patients.
- National Strategic Collaborations: AstraZeneca will distribute $2.3 million to 10 organizations under the National Strategic Collaborations program, supporting initiatives related to lung disease, lung and breast cancer, and cardiology, aimed at addressing barriers for underserved populations.
- Positive Market Reaction: AstraZeneca's stock rose 3.29% in premarket trading to $199.77, reflecting investor recognition of the company's proactive actions in the health equity space.
See More
Paramount Enhances Warner Bros. Bid with Ticking Fee
- Bid Enhancement: Paramount has added a $0.25 per share 'ticking fee' to its hostile bid for Warner Bros. Discovery, maintaining its cash offer at $30 per share, which reflects its confidence in swift regulatory approval.
- Financial Commitment: Paramount will cover a $2.8 billion termination fee to Netflix if the merger with Warner Bros. is canceled, demonstrating its strong commitment to providing value to Warner Bros. shareholders.
- Nuclear IPO Filing: Holtec International has confidentially filed for an IPO that could value the company at over $10 billion, making it one of the largest in the nuclear sector, with annual revenues exceeding $500 million.
- AstraZeneca's Drug Strategy: AstraZeneca plans to introduce competitively priced weight-loss drugs to address market pressures in the U.S., with CEO Pascal Soriot emphasizing the enormous global demand and the potential for lower production costs to expand access.
See More
